Neonatal abstinence syndrome (NAS) occurs when newborn infants experience withdrawal symptoms after birth due to being exposed to drugs like opioids, benzodiazepines, or alcohol in the womb. Symptoms of NAS vary based on the type and amount of drug used but often begin within a week of birth. Diagnosis involves screening the mother's drug use and testing the newborn. Treatment may involve non-pharmacological comfort measures for mild cases or medications to relieve withdrawal for more severe cases. Babies with NAS often need to stay in the hospital for monitoring and treatment for up to 6 months. Preventing NAS requires mothers abstaining from substance use during pregnancy.
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...ErikaAGoyer
NATIONAL PERINATAL ASSOCIATION CONFERENCE 2014 - Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed)
- Chris Cooper, MSN, NNP-CB, APRN and Dawn Forbes, MD
Intrauterine drug exposure and nas newest10 17 14ErikaAGoyer
NATIONAL PERINATAL ASSOCIATION CONFERENCE 2014 - Intrauterine Drug Exposure and the Management of Neonatal Abstinence Syndrome
- Evelyn Fulmore, Pharm. D., McLeod Regional Medical Center
Intrauterine Drug Exposure and the Management of Neonatal Abstinence SyndromeErikaAGoyer
Intrauterine Drug Exposure and the
Management of Neonatal Abstinence Syndrome:
The participant will be able to: Identify the impact of
poly-drug exposure and NAS in the neonate; describe
the current pharmacologic therapies used to manage
NAS in the neonate and identify short and long term
outcomes in the neonate with intrauterine drug
exposure.
Neonatal abstinence syndrome is a growing problem in Tennessee. NAS happens when babies are in contact with
medications or illegal drugs in the womb. These babies form a physical dependence on the drug used by their mother
during pregnancy. After birth, they experience withdrawal just like adults. Withdrawal symptoms vary, but can include high-pitched crying, tremors, hyperactive reflexes and inconsolability. In some cases, drug dependent babies suffer seizures as well.
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...ErikaAGoyer
NATIONAL PERINATAL ASSOCIATION CONFERENCE 2014 - Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed)
- Chris Cooper, MSN, NNP-CB, APRN and Dawn Forbes, MD
Intrauterine drug exposure and nas newest10 17 14ErikaAGoyer
NATIONAL PERINATAL ASSOCIATION CONFERENCE 2014 - Intrauterine Drug Exposure and the Management of Neonatal Abstinence Syndrome
- Evelyn Fulmore, Pharm. D., McLeod Regional Medical Center
Intrauterine Drug Exposure and the Management of Neonatal Abstinence SyndromeErikaAGoyer
Intrauterine Drug Exposure and the
Management of Neonatal Abstinence Syndrome:
The participant will be able to: Identify the impact of
poly-drug exposure and NAS in the neonate; describe
the current pharmacologic therapies used to manage
NAS in the neonate and identify short and long term
outcomes in the neonate with intrauterine drug
exposure.
Neonatal abstinence syndrome is a growing problem in Tennessee. NAS happens when babies are in contact with
medications or illegal drugs in the womb. These babies form a physical dependence on the drug used by their mother
during pregnancy. After birth, they experience withdrawal just like adults. Withdrawal symptoms vary, but can include high-pitched crying, tremors, hyperactive reflexes and inconsolability. In some cases, drug dependent babies suffer seizures as well.
Drug use in midwifery and obstetrical
1. Defination of Mala-n
2.Mode of intake of mala-n
3.Mode of action of mala-n.
4. Advantages of mala-n
5. Disadvantages of mala-n
6. contraindication of mala-n
7. Side of mala-n
Newborn Screening | Infant Care | Health Care | Baby's First Testjohndemello7
Baby's First Test is the nation's newborn screening education center for parents, health professionals, and the public on the newborn screening system.
Visit http://www.babysfirsttest.org/
Nocturnal enuresis is one of the commonest problems in childhood. This presentation contains details on prevalence, diagnostic criteria and treatment modalities.
A slight description on contraception, its types along with a brief explanation on Oral Contraceptives. Types of oral contraceptives, it's types, mechanism of action, contraindications, dosing, advantages, disadvantages, risk, benefit amd recent research trends.
ABSTRACT:
Nocturnal enuresis or night time urinary incontinence, commonly called bedwetting or sleep wetting, is involuntary urination while asleep after the age at which bladder control usually occurs. Bedwetting is a common childhood urologic complaint and one of the most common pediatric health issues. Enuresis is notoriously difficult to treat and is frequently related to psychological factors. The emotional impact of enuresis on a child and family is considerable. Children with enuresis are commonly punished and are at risk for emotional and physical abuse. Numerous studies of children with enuresis report feelings of embarrassment and anxiety, loss of self-esteem, and effects on self-perception, interpersonal relationships, quality of life, and school performance. The condition can be successfully treated with homoeopathic medicines but require a long term follow – up. The present article focuses on management of this medical condition with our medicines.
Drug use in midwifery and obstetrical
1. Defination of Mala-n
2.Mode of intake of mala-n
3.Mode of action of mala-n.
4. Advantages of mala-n
5. Disadvantages of mala-n
6. contraindication of mala-n
7. Side of mala-n
Newborn Screening | Infant Care | Health Care | Baby's First Testjohndemello7
Baby's First Test is the nation's newborn screening education center for parents, health professionals, and the public on the newborn screening system.
Visit http://www.babysfirsttest.org/
Nocturnal enuresis is one of the commonest problems in childhood. This presentation contains details on prevalence, diagnostic criteria and treatment modalities.
A slight description on contraception, its types along with a brief explanation on Oral Contraceptives. Types of oral contraceptives, it's types, mechanism of action, contraindications, dosing, advantages, disadvantages, risk, benefit amd recent research trends.
ABSTRACT:
Nocturnal enuresis or night time urinary incontinence, commonly called bedwetting or sleep wetting, is involuntary urination while asleep after the age at which bladder control usually occurs. Bedwetting is a common childhood urologic complaint and one of the most common pediatric health issues. Enuresis is notoriously difficult to treat and is frequently related to psychological factors. The emotional impact of enuresis on a child and family is considerable. Children with enuresis are commonly punished and are at risk for emotional and physical abuse. Numerous studies of children with enuresis report feelings of embarrassment and anxiety, loss of self-esteem, and effects on self-perception, interpersonal relationships, quality of life, and school performance. The condition can be successfully treated with homoeopathic medicines but require a long term follow – up. The present article focuses on management of this medical condition with our medicines.
Prenatal development: germinal, embryonic &fetal period; Factors that can have a serious negative impact on the development of the unborn: maternal health, radiation, maternal nutrition, medication and drugs, age of the parents, diseases in the pregnant woman and the emotional state of the mother.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
3.
Neonatal Abstinence Syndrome
Neonatal withdrawal or Neonatal Abstinence Syndrome (NAS) is a withdrawal
syndrome of infants after birth caused by in utero exposure to licit or illicit
drugs, especially opiates.
There are two types of NAS:
* Prenatal
* Postnatal
Prenatal NAS is caused by discontinuation of drugs taken by the pregnant
mother, while postnatal NAS is caused by discontinuation of drugs directly to
the infant.
4.
Causes
Neonatal abstinence syndrome may occur when a pregnant woman takes
drugs such as heroin, codeine, oxycodone (Oxycontin), methadone or
buprenorphine.
These and other substances pass through the placenta that connects the baby
to its mother in the womb. The baby becomes dependent on the drug along
with the mother.
Because the baby is no longer getting the drug after birth, withdrawal
symptoms may occur as the drug is slowly cleared from the baby's system.
6.
Withdrawal symptoms also may occur in babies exposed to alcohol,
benzodiazepines, barbiturates, and certain antidepressants (SSRIs)
while in the womb .
Babies of mothers who use other addictive drugs (nicotine,
amphetamines, cocaine, marijuana) may have long-term problems.
7.
Symptoms
The symptoms of neonatal abstinence syndrome depend on:
* The type of drug the mother used
* How the body breaks down and clears the drug
* How much of the drug she was taking
* How long she used the drug
* Whether the baby was born full-term or premature
Symptoms often begin within 1 to 3 days after birth, but may take up to a week to
appear. Because of this, the baby will most often need to stay in the hospital for
observation and monitoring for up to a week.
10.
Exams & Tests
Many other conditions can produce the same symptoms as NAS.
To help make a diagnosis, the health care provider will ask questions about the
mother's drug use.
* The mother may be asked about which drugs she took during
pregnancy, and when she last took them.
* The mother's urine may be screened for drugs as well.
11. Tests that may be done to help diagnose withdrawal in a newborn include:
CBC, hair analysis, drug screen (of mother and infant), thyroid levels,
electrolytes, and blood glucose. Chest x-rays can confirm or infirm the
presence of heart defects.
Neonatal abstinence syndrome scoring system, which assigns points based on
each symptom and its severity. The infant's score can help determine
treatment.
Toxicology (drug) screen of urine and of first bowel movements (meconium).
14.
Treatment
Treatment depends on:
* The drug involved
* The infant's overall health and abstinence scores
* Whether the baby was born full-term or premature
The health care team will watch the newborn carefully for up to a week after
birth for signs of withdrawal, feeding problems, and weight gain. Babies who
vomit or who are very dehydrated may need to get fluids through a vein (IV).
15. Infants with neonatal abstinence syndrome are often fussy and hard to calm. Tips
to calm the infant down include measures referred to as "TLC" (tender loving care):
* Gently rocking the child.
* Reducing noise and lights.
* Swaddling the baby in a blanket.
Some babies with severe symptoms need medicines such as methadone and
morphine to treat withdrawal symptoms.
The goal of treatment is to prescribe the infant a drug similar to the one the mother
used during pregnancy and slowly decrease the dose over time. This helps wean
the baby off the drug and relieves some withdrawal symptoms.
16. If the symptoms are severe, a second medicine such as phenobarbital or
clonidine may be added.
Babies with this condition often have severe diaper rash or other areas of skin
breakdown. This requires treatment with special ointment or cream.
Babies may also have problems with feeding or slow growth. These problems
may require:
* Higher-calorie feedings that provide greater nutrition
* Smaller portions given more often
17.
Prognosis
Treatment helps relieve symptoms of withdrawal. Even after medical
treatment for NAS is over and babies leave the hospital, they may need
extra "TLC" for weeks or months.
18.
Possible Complications
Drug and alcohol use during pregnancy can lead to many problems.
These may include:
* Birth defects
* Low birth weight
* Premature birth
* Small head circumference
* Sudden Infant Death Syndrome (SIDS)
* Problems with development and behavior
Neonatal abstinence syndrome treatment can last from 1 week to 6 months. Even
after medical treatment for NAS is over and babies leave the hospital, they may
need extra "TLC" for weeks or months.
19.
Preventions
Neonatal withdrawal is prevented by the mother abstaining from substance
abuse. Prescribed medication may have to be discontinued during the
pregnancy to prevent addiction by the baby.
Women can discuss all medicines, and alcohol and tobacco use with their
health care provider and get assistance to help stop drug use as soon as
possible. Indications that a woman needs help if she is:
* Using drugs non-medically
* Using drugs not prescribed to you
* Using alcohol or tobacco
20.
References
Bencke M, Smith VC, Committee on Substance Abuse, Committee on Fetus and
Newborn. American Academy of Pediatrics. Prenatal substance abuse: short- and
long-term effects on the exposed fetus (technical report). Pediatrics.
2013;131(3):e1009-24. PMID: 23439891 www.ncbi.nlm.nih.gov/pubmed/23439891.
Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn: American
Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-
60. PMID: 22291123 www.ncbi.nlm.nih.gov/pubmed/22291123.
Lawn C, Aiton N. The baby of a substance-abusing mother. In: Rennie JM, ed. Rennie
and Roberton's Textbook of Neonatology. 5th ed. London, UK: Elsevier Churchill
Livingstone; 2012:chap 26.
Patrick SW, et al. Prescription opioid epidemic and infant outcomes. Pediatrics.
2015;135:842-850.